{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T14:49:16Z","timestamp":1776178156343,"version":"3.50.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Upper gastrointestinal malignancies bear a high morbidity and mortality burden. Curative treatment requires a multimodal approach, subjecting patients to preoperative chemotherapy or chemoradiation to downstage the tumor before resection. Various preoperative regimens exist but there is no tailor-made approach based on the tumor sensitivity for the individual patient. This predisposes a considerable subset of patients to inadequate treatment and highlights the need for personalized medicine, for which the potential of patient-derived cancer organoids (PDCOs) was investigated. PDCOs were established from pre-treatment biopsies of two gastric and four esophageal cancer patients, and compared to previously established PDCOs derived from four gastric and two esophageal resections post-neoadjuvant treatment. PDCO sensitivity, defined as area under the dose\u2013response curve, was determined to in vitro chemotherapy (epirubicin, oxaliplatin, capecitabine and 5-fluorouracil, leucovorin, oxaliplatin, docetaxel) and chemoradiation (carboplatin, paclitaxel, radiotherapy). The PDCOs were established from 55% of the pre-treatment biopsies (derived from four of six patients), and demonstrated differential sensitivity to the treatment screens. PDCOs initiated from pre-treatment tissue were more sensitive than those derived from post-treatment tissue. In addition, drug screen sensitivity of pre-treatment PDCOs correlated well with patient response in terms of tumor regression grade. The current results provide a proof of principle and offer recommendations for a structured pipeline to more efficiently establish, validate and screen a larger cohort of pre-treatment PDCOs.<\/jats:p>","DOI":"10.1093\/dote\/doaf115","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:27:31Z","timestamp":1768307251000},"source":"Crossref","is-referenced-by-count":0,"title":["Patient-derived cancer organoids to tailor personalized treatment strategies in upper gastrointestinal malignancies"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0512-6545","authenticated-orcid":false,"given":"Ingrid A","family":"Franken","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Utrecht, Utrecht University , Utrecht ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Busslinger","sequence":"additional","affiliation":[{"name":"Organoid Laboratory, Hubrecht Institute , Utrecht ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bas L A M","family":"Weusten","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Medical Center Utrecht, Utrecht University , Utrecht ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lodewijk A A","family":"Brosens","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht, Utrecht University , Utrecht ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelle P","family":"Ruurda","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University Medical Center Utrecht, Utrecht University , Utrecht ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Haj Mohammad","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Utrecht, Utrecht University , Utrecht ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Mook","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University , Utrecht ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Clevers","sequence":"additional","affiliation":[{"name":"Organoid Laboratory, Hubrecht Institute , Utrecht ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7134-261X","authenticated-orcid":false,"given":"Richard","family":"Van Hillegersberg","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University Medical Center Utrecht, Utrecht University , Utrecht ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"issue":"5","key":"2026041409571042800_ref1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"issue":"1","key":"2026041409571042800_ref2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"26","key":"2026041409571042800_ref3","doi-asserted-by":"publisher","first-page":"7933","DOI":"10.3748\/wjg.v21.i26.7933","article-title":"Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries","volume":"21","author":"Arnal","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"2","key":"2026041409571042800_ref4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s10120-005-0321-z","article-title":"Recent advances in multimodal treatment for gastric cancer: a review","volume":"8","author":"Lordick","year":"2005","journal-title":"Gastric Cancer"},{"issue":"1","key":"2026041409571042800_ref5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"2026041409571042800_ref6","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","article-title":"Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial","volume":"17","author":"Al-Batran","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"2026041409571042800_ref7","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.2017.35.15_suppl.4004","article-title":"Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil\/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF\/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial","volume":"35","author":"Al-Batran","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"2026041409571042800_ref8","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"issue":"22","key":"2026041409571042800_ref9","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Hagen","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"2026041409571042800_ref10","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11&lt;2680::AID-CNCR2820731105&gt;3.0.CO;2-C","article-title":"Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations","volume":"73","author":"Mandard","year":"1994","journal-title":"Cancer"},{"issue":"4","key":"2026041409571042800_ref11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa2409408","article-title":"Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer","volume":"392","author":"Hoeppner","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"2026041409571042800_ref12","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1200\/JCO.2025.43.16_suppl.4014","article-title":"Recurrence patterns in the prospective, randomized, controlled, multicenter phase III ESOPEC trial comparing perioperative chemotherapy with preoperative chemoradiotherapy in patients with esophageal adenocarcinoma","volume":"43","author":"Hoeppner","year":"2025","journal-title":"Ann Oncol"},{"issue":"5","key":"2026041409571042800_ref13","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","article-title":"Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett\u2019s epithelium","volume":"141","author":"Sato","year":"2011","journal-title":"Gastroenterology"},{"issue":"7702","key":"2026041409571042800_ref14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-018-0024-3","article-title":"Intra-tumour diversification in colorectal cancer at the single-cell level","volume":"556","author":"Roerink","year":"2018","journal-title":"Nature."},{"issue":"4","key":"2026041409571042800_ref15","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","article-title":"Prospective derivation of a living organoid biobank of colorectal cancer patients","volume":"161","author":"Wetering","year":"2015","journal-title":"Cell"},{"issue":"6378","key":"2026041409571042800_ref16","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"issue":"3","key":"2026041409571042800_ref17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jcmgh.2017.12.013","article-title":"The esophageal organoid system reveals functional interplay between notch and cytokines in reactive epithelial changes","volume":"5","author":"Kasagi","year":"2018","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"6","key":"2026041409571042800_ref18","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.stem.2018.09.016","article-title":"A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening","volume":"23","author":"Yan","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"4","key":"2026041409571042800_ref19","doi-asserted-by":"publisher","first-page":"190274","DOI":"10.1098\/rsob.190274","article-title":"The potential and challenges of patient-derived organoids in guiding the multimodality treatment of upper gastrointestinal malignancies","volume":"10","author":"Busslinger","year":"2020","journal-title":"Open Biol"},{"issue":"1","key":"2026041409571042800_ref20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-023-01919-3","article-title":"Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold","volume":"23","author":"Schm\u00e4che","year":"2024","journal-title":"Mol Cancer"},{"issue":"7","key":"2026041409571042800_ref21","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1158\/2159-8290.CD-18-1522","article-title":"Oral mucosal organoids as a potential platform for personalized cancer therapy","volume":"9","author":"Driehuis","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"2026041409571042800_ref22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","article-title":"Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer","volume":"26","author":"Yao","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"2","key":"2026041409571042800_ref23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1136\/gutjnl-2017-314549","article-title":"Human gastric cancer modelling using organoids","volume":"68","author":"Seidlitz","year":"2019","journal-title":"Gut"},{"issue":"4","key":"2026041409571042800_ref24","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.cell.2018.07.027","article-title":"Divergent routes toward Wnt and R-spondin niche independency during human gastric carcinogenesis","volume":"174","author":"Nanki","year":"2018","journal-title":"Cell"},{"issue":"1","key":"2026041409571042800_ref25","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1038\/s41467-018-05190-9","article-title":"Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics","volume":"9","author":"Li","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"2026041409571042800_ref26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jcmgh.2018.09.008","article-title":"An organoid-based preclinical model of human gastric cancer","volume":"7","author":"Steele","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"9","key":"2026041409571042800_ref27","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1245\/s10434-018-6662-8","article-title":"Development of patient-derived gastric cancer organoids from endoscopic biopsies and surgical tissues","volume":"25","author":"Gao","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2026041409571042800_ref28","doi-asserted-by":"publisher","first-page":"21304","DOI":"10.1038\/s41598-021-00706-8","article-title":"Patient-derived organoids as a platform for modeling a patient\u2019s response to chemoradiotherapy in esophageal cancer","volume":"11","author":"Karakasheva","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"2026041409571042800_ref29","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat Methods"},{"issue":"7","key":"2026041409571042800_ref30","doi-asserted-by":"publisher","first-page":"101627","DOI":"10.1016\/j.xcrm.2024.101627","article-title":"Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer","volume":"5","author":"Zhao","year":"2024","journal-title":"Cell Rep Med"},{"issue":"1","key":"2026041409571042800_ref31","doi-asserted-by":"publisher","first-page":"14514","DOI":"10.1038\/s41598-020-71589-4","article-title":"Towards personalized induction therapy for esophageal adenocarcinoma: organoids derived from endoscopic biopsy recapitulate the pre-treatment tumor","volume":"10","author":"Derouet","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"2026041409571042800_ref32","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026041409571042800_ref33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"2026041409571042800_ref34","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.stem.2022.04.006","article-title":"Patient-derived micro-organospheres enable clinical precision oncology","volume":"29","author":"Ding","year":"2022","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2026041409571042800_ref35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13046-024-02980-6","article-title":"Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response","volume":"43","author":"Smabers","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"2026041409571042800_ref36","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","article-title":"Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (neo-AEGIS): an open-label, randomised, phase 3 trial","volume":"8","author":"Reynolds","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"2026041409571042800_ref37","doi-asserted-by":"publisher","first-page":"5566","DOI":"10.18632\/oncotarget.13328","article-title":"Prognostic gene expression profiling in esophageal cancer: a systematic review","volume":"8","author":"Visser","year":"2017","journal-title":"Oncotarget"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/39\/1\/doaf115\/66556765\/doaf115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/39\/1\/doaf115\/66556765\/doaf115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:57:17Z","timestamp":1776175037000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doaf115\/8439515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,9]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doaf115","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"value":"1120-8694","type":"print"},{"value":"1442-2050","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,9]]},"article-number":"doaf115"}}